Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational Uncertainty. (PubMed, Cureus) - Sep 18, 2026 - "In addition, zuranolone was not approved as a broad treatment for major depressive disorder, underscoring the need to avoid extrapolating postpartum depression findings to all depressive populations. Overall, zuranolone should be understood as a meaningful but evidence-bounded innovation in perinatal psychopharmacology, whose clinical value will depend on careful patient selection, safety counseling, follow-up, equitable access, and continued evidence generation."
Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Postpartum Depression • Psychiatry
|
|
Esteban Zavaleta-Monestel; Jeaustin Mora-Jiménez; Katherine González-Aguilar; Luis Guillermo Herrera-Jiménez; Ricardo Millán González
|